Can a patient with a penicillin allergy be given Merrem (meropenem)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Meropenem Administration in Penicillin-Allergic Patients

Yes, meropenem (Merrem) can be safely administered to patients with penicillin allergy without prior allergy testing, regardless of whether the patient had an immediate-type or non-severe delayed-type reaction. 1, 2, 3

Guideline-Based Recommendations

Multiple major guidelines strongly recommend administering carbapenems, including meropenem, to penicillin-allergic patients without testing or additional precautions:

  • The Dutch Working Party on Antibiotic Policy (SWAB) recommends that patients with suspected immediate-type penicillin allergy can receive any carbapenem without prior allergy testing, irrespective of severity or time since the index reaction 1

  • The American Academy of Allergy, Asthma, and Immunology provides a conditional recommendation with moderate certainty of evidence that carbapenems can be administered to penicillin-allergic patients without testing 3

  • These recommendations apply to both immediate-type allergies (including anaphylaxis) and non-severe delayed-type penicillin allergies 1, 3

Evidence Supporting Safety

The cross-reactivity rate between penicillins and carbapenems is extremely low:

  • A systematic review of 1,127 patients with proven penicillin allergy demonstrated a cross-reactivity rate of only 0.87% (95% CI: 0.32%-2.32%) between penicillins and any carbapenem 2, 3

  • Among 295 patients with positive penicillin skin tests, only 1 patient (0.3%) had a potentially IgE-mediated reaction to carbapenems 3

  • A prospective study of 211 patients with skin test-confirmed penicillin allergy showed that all patients tolerated carbapenems without adverse reactions 3

  • A prospective clinical study of 110 patients with both non-anaphylactic (59 patients) and anaphylactic (51 patients) penicillin allergic reactions tolerated prolonged meropenem therapy (1-4 weeks) safely without any allergic reactions 4

FDA Drug Label Considerations

The FDA label for meropenem includes important warnings but does not contraindicate use in penicillin-allergic patients:

  • Meropenem is contraindicated only in patients with known hypersensitivity to meropenem itself or who have demonstrated anaphylactic reactions to beta-lactams 5

  • The label notes that individuals with a history of penicillin hypersensitivity have experienced severe hypersensitivity reactions when treated with another β-lactam, and recommends inquiring about previous hypersensitivity reactions before initiating therapy 5

  • However, this warning reflects general β-lactam precautions and does not specifically contraindicate meropenem use in penicillin-allergic patients 5

Practical Clinical Approach

Administer meropenem directly when clinically indicated:

  • Give meropenem without delay when clinically necessary 3

  • No penicillin skin testing is required before meropenem administration 3

  • Monitor for hypersensitivity reactions during the first dose, particularly in patients with a history of severe reactions 2, 3

Special Circumstances Requiring Additional Caution

Consider a graded drug challenge or enhanced monitoring in specific situations:

  • Patients with multiple drug allergies 3

  • Patients with significant anxiety about receiving the medication 3

  • Patients with severe delayed cutaneous reactions to penicillins (such as Stevens-Johnson syndrome, toxic epidermal necrolysis, or DRESS syndrome) 3

Common Pitfalls to Avoid

Do not unnecessarily withhold meropenem from penicillin-allergic patients:

  • Avoiding meropenem in penicillin-allergic patients leads to suboptimal patient outcomes and use of less effective second-line antibiotics 3, 6

  • Do not confuse carbapenem cross-reactivity (0.87%) with cephalosporin cross-reactivity (2-4% for dissimilar side chains, up to 16% for similar side chains) 1, 3

  • The historical practice of avoiding all β-lactams in penicillin-allergic patients is not supported by current evidence for carbapenems 4, 7

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Meropenem Safety in Patients with Penicillin Allergy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Meropenem Administration in Patients with Penicillin Allergy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Meropenem allergy testing performed at the bedside of hospitalized patients labelled with a penicillin allergy.

Allergology international : official journal of the Japanese Society of Allergology, 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.